AVANT BIO LLC, the growth equity firm investing in life science industrials and enabling technologies, today announced the ...
UPPSALA, SE / ACCESS Newswire / October 26, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime invites investors, analysts, and ...
LUND, SE / ACCESS Newswire / October 26, 2026 / Cantargia AB (publ)(STO:CANTA), a clinical-stage biotechnology company ...
Offers a potential new standard of care through an all-oral, biomarker-driven frontline strategy for MET-overexpressing, EGFR ...
Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Co ...
A new scientific avenue for daridorexant: Idorsia to advance development in autism spectrum disorder
In a Phase 2 study in pediatric insomnia disorder, in addition to marked improvements in sleep measures, daridorexant 50 mg showed an unexpected pattern of improvement in affect and behavior, ...
Financial visibility extended to second quarter of 2028 All existing debt holders, including the CEO and two members of the Supervisory Board, are extending the maturity of the debt from May 2027 to ...
Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the ...
In a prespecified interim analysis reviewed by the Independent Data Monitoring Committee (IDMC), HARMONi-GI1 met its primary ...
The phase III Krascendo 1 results demonstrate the potential for divarasib to become a new standard of care for people with ...
Risk, Heavily Pretreated Multiple Myeloma, Supporting Further Development of the Company’s TCE Pipeline. NANJING, China, ...
Responses were deep and durable, with 65% ongoing at clinical cutoff; Results support continued evaluation of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results